Table 1 Main characteristics and results of the eligible studies

From: The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis

First author	Year	Histology	Stage	N pts	Laboratory method	HR estimation	Survival results
Ahrendt	2002	NSCLC	I–IIIA	60	PCR-seq	No data	NC
Andjelic	2001	NSCLC	IIIA	21	PCR-SSCP	No data	Negative
Broermann	2002	NSCLC	III	28	PCR-RFLP	No data	NS
Cho	1997	NSCLC	I–IIIB	58	PCR-SSCP	Survival curves	Negative
De Gregorio	1998	ADC	I–IV	184	PCR	No data	NS
Dingemans	1999	SCLC	ANY	93	IHC	Survival curves	NS
Fu	1999	NSCLC	I–IIIB	158	IHC	No data	NS
Fukuyama	1997	NSCLC	I–IV	159	PCR-RFLP	Survival curves	Negative
Graziano	1999	NSCLC	I–II	213	PCR	Log rank	NS
Greatens	1998	NSCLC	I–IV	101	PCR-SSCP	No data	NS
Grossi	2003	NSCLC	I–IIIA	249	PCR	HR	NS
Harada	1992	NSCLC	I–IV	94	IHC	Survival curves	Negative
Huang	1998	NSCLC	I–IIIB	144	PCR-SSCP	Survival curves	Negative
Kang	2001	NSCLC	I–IIIB	61	IHC	HR	NS
Kashii	1995	ALL	I–IV	97	PCR-SSCP	No data	NS
Keohavong	1996	NSCLC	I–IV	126	PCR-DGGE	Log rank	NS
Kern	1994	ADC	I–IV	44	PCR-ASO	HR	NS
Kim	1998	NSCLC	I–IV	238	IHC	HR	NS
Komiya	1997	NSCLC	I–IIIA	137	IHC	Survival curves	NS
Kwiatkowski	1998	NSCLC	I	244	PCR-RFLP	Log rank	NS
Li	1994	ADC	I–?	41	PCR-dot blot	No data	NS
Mitsudomi	1991	ALL	I–IV	66	PCR-RFLP	Log rank	NS
Miyake	1999	NSCLC	I–IIIB	187	PCR-SSCP	No data	Negative
Moldvay	2000	NSCLC	I–IV	227	IHC	Log rank	NS
Nelson	1999	NSCLC	I–IV	355	PCR-RFLP	Survival curves	Negative
Nemunaitis	1998	ADC+LC	I–IV	103	PCR-RFLP	Survival curves	NS
Pifarre	1997	NSCLC	I–IIIA	64	PCR-SSCP	No data	NC
Ramirez	2003	NSCLC	I–IV	50	PCR	Survival curves	NS
Rodenhuis	1997	ADC	III–IV	62	EPCR	Log rank	NS
Rosell	1997	NSCLC	I	35	PCR-SSCP	Log rank	NS
Rosell	1993	NSCLC	I–IIIA	66	PCR-RFLP	Log rank	Negative
Schiller	2001	NSCLC	II–IIIA	184	PCR-RFLP	HR	NS
Schneider	2000	NSCLC	I–IIIA	103	PCR-SSCP	No data	NS
Shoji	2002	NSCLC	I–IIIA	233	IHC	Survival curves	Positive
Siegfried	1997	ADC	I–IV	181	PCR-DGGE	Survival curves	NS
Silini	1994	ADC	I–IV	109	PCR-DGGE	Survival curves	NS
Slebos	1990	ADC	I–IIIA	69	PCR-ASO	Log rank	Negative
Sugio	1992	ADC	I–IV	115	PCR-dot blot	Survival curves	NS
Tomizawa	2002	ADC	I	110	PCR-seq	Log rank	NS
Visscher	1997	ADC	I–IV	31	PCR-SSCP	No data	NS
Volm (KRAS2)	1993	NSCLC	I–III	206	IHC	No data	NS
Wang	1998	ALL	I–IV	53	PCR-seq	HR	NS
Westra	1993	ADC	I–III	57	PCR-ASO	No data	NS

N pts=number of patients; HR=hazard ratio; NSCLC=non-small-cell lung cancer; ADC=adenocarcinoma; SCLC=small-cell lung carcinoma; LC=large cell; NC=nonconclusive; NS=nonsignificative; PCR=polymerase chain reaction; SSCP=single-strand conformation polymorphism; RFLP=restriction fragment length polymorphism; ASO=allele-specific oligonucleotide hybridisation; DGGE=denaturating gradient gel electrophoresis; seq=PCR followed by sequencing of olignucleotide; EPCR=mutant-enriched PCR; IHC=immunohistochemistry; HR estimation=description of the methods used to estimate the individual HR according the three corresponding of the three different methods described in the statistics paragraph.

Back to article page

Table 1 Main characteristics and results of the eligible studies

Search

Quick links